## SEC Form 4

SEC FOI							יחווי									NI				
FORM 4 UNI			NILE	DSIAI	ES \$	SEC			S AN gton, D.C		49 49	IGE		VIVIV	112210		OM	B APPRO	VAL	
to Section 16. Form 4 or Form 5 obligations may continue. See					IT OF CHANGES IN BENEFICIAL OWNERSHIP												OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
Instruc	uon 1(b).			Fileu	or Se	ction 3	30(h) o	of the li	nvestme	nt Co	mpany Act of									
1. Name and Address of Reporting Person <sup>*</sup> BIOGEN INC.					2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC [ SGMO]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle) 225 BINNEY ST.					3. Date of Earliest Transaction (Month/Day/Year) 09/26/2023										Officer (give title Other (specify below) below)					
(Street) CAMBRIDGE MA 02142					4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication															
											saction was ma ons of Rule 10					uction or writ	tten pl	lan that is inte	ended to	
		Table	I - No	n-Deriva	tive S	Secu	rities	s Acq	uired	, Dis	posed of	, or	Bene	eficia	lly Own	ed				
Da				2. Transact Date (Month/Day		Execution Date		Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			A) or 3, 4 and	I Securi Benefi	cially I Following	Foi (D)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A (D	() or ()	Price	Transa	action(s) 3 and 4)			(Instr. 4)	
Common Stock 09/26/24					2023	23		s		6,000,000	) D \$0		\$0.5	5 17,0	17,652,466		I	By Biogen MA Inc.		
		Та	ble II -								osed of, o convertib				y Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa	ansaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			isable and ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or Nun of	ount nber res	ber					
	nd Address of EN INC.	f Reporting Person	r		I															
(Last) 225 BIN	NEY ST.	(First)	(Mi	iddle)		-														
(Street) CAMBRIDGE MA 021			142																	
(City)		(State)	(Zij	p)																
	nd Address o I <u>MA Inc</u>	of Reporting Person <sup>*</sup>	r																	
(Last) 225 BIN	NEY ST.	(First)	(Mi	iddle)																
(Street)	RIDGE	MA	02	142																

Explanation of Responses:

(State)

1. Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

(Zip)

Remarks:

(City)

Michael Dambach, Vice President and Treasurer BIOGEN MA INC. By: /s/ Michael Dambach, Vice President and Treasurer \*\* Signature of Reporting Person

09/28/2023

Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.